Empagliflozin vs Upadacitinib

Empagliflozin vs Upadacitinib: Overview

This comparison examines the pharmacological differences between Empagliflozin and Upadacitinib.

Mechanism of Action

Empagliflozin: Selective SGLT2 inhibitor reducing renal glucose reabsorption.

Upadacitinib: Selective JAK1 inhibitor reducing signaling from cytokines implicated in autoimmune diseases.

Pharmacokinetics

Half-life: Empagliflozin — 12.4 hours; Upadacitinib — 9-14 hours.

Chemical Properties

Molecular Formula: Empagliflozin — C23H27ClO7; Upadacitinib — C17H19F3N6O.

Molecular Weight: Empagliflozin — 450.9100 g/mol; Upadacitinib — 380.3700 g/mol.

Type: Empagliflozin — Small molecule; Upadacitinib — Small molecule.